RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Inhibitor Therapeutics P/E 2024

Inhibitor Therapeutics P/E

-2.1

Inhibitor Therapeutics Dividend yield

Ticker

INTI

ISIN

US45720M1053

WKN

A2PQRT

As of May 2, 2024, Inhibitor Therapeutics's P/E ratio was -2.1, a -173.94% change from the 2.84 P/E ratio recorded in the previous year.

The Inhibitor Therapeutics P/E history

Inhibitor Therapeutics Aktienanalyse

What does Inhibitor Therapeutics do?

Inhibitor Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for cancer and autoimmune diseases. The company was founded in the USA in 2008 and has since established itself as a leading player in the biotech industry. The history of Inhibitor Therapeutics Inc began with the discovery of a promising molecule called ITI-007, which could represent a novel treatment option for schizophrenia. After extensive preclinical tests and clinical studies, ITI-007 was eventually approved by the FDA and brought to market. The medication has proven to be very successful and is used by many patients worldwide. Today, Inhibitor Therapeutics Inc's business model includes several different divisions. In addition to schizophrenia therapy, the company focuses on the development of innovative cancer therapies based on the blockage of enzymes and proteins responsible for tumor growth. The company utilizes a wide range of technologies to develop the best therapies for different types of cancer. Inhibitor Therapeutics Inc's products also include a range of diagnostics and biomarkers that contribute to the early detection and treatment of cancer. These technologies enable personalized medicine and help improve the effectiveness of therapies. Overall, the goal of Inhibitor Therapeutics Inc is to improve the lives of millions of people through groundbreaking innovations in cancer and autoimmune therapy. The company works closely with leading scientific institutions and clinics to translate the latest research findings into clinical practice. An important part of Inhibitor Therapeutics Inc's corporate culture is promoting diversity and inclusion. The company actively strives to create a work environment that is open and inclusive, where every employee has the opportunity to reach their full potential. Overall, Inhibitor Therapeutics Inc is an emerging company specializing in the development of innovative therapies for cancer and autoimmune diseases. With a wide range of technologies and products, a strong corporate culture, and a dedicated team of employees, the company is well-positioned to continue growing in the coming years and make its vision of better health for all a reality. Inhibitor Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Inhibitor Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Inhibitor Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Inhibitor Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Inhibitor Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Inhibitor Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Inhibitor Therapeutics Stock

What is the price-to-earnings ratio of Inhibitor Therapeutics?

The price-earnings ratio of Inhibitor Therapeutics is currently -2.1.

How has the price-earnings ratio of Inhibitor Therapeutics changed compared to last year?

The price-to-earnings ratio of Inhibitor Therapeutics has increased by -173.94% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Inhibitor Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Inhibitor Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Inhibitor Therapeutics affect the company?

An increase in the price-earnings ratio of Inhibitor Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Inhibitor Therapeutics affect the company?

A decrease in the price-earnings ratio of Inhibitor Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Inhibitor Therapeutics?

Some factors that influence the price-earnings ratio of Inhibitor Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Inhibitor Therapeutics pay?

Over the past 12 months, Inhibitor Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibitor Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Inhibitor Therapeutics?

The current dividend yield of Inhibitor Therapeutics is .

When does Inhibitor Therapeutics pay dividends?

Inhibitor Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inhibitor Therapeutics?

Inhibitor Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Inhibitor Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inhibitor Therapeutics located?

Inhibitor Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inhibitor Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inhibitor Therapeutics from 5/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/2/2024.

When did Inhibitor Therapeutics pay the last dividend?

The last dividend was paid out on 5/2/2024.

What was the dividend of Inhibitor Therapeutics in the year 2023?

In the year 2023, Inhibitor Therapeutics distributed 0 USD as dividends.

In which currency does Inhibitor Therapeutics pay out the dividend?

The dividends of Inhibitor Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Inhibitor Therapeutics

Our stock analysis for Inhibitor Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibitor Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.